An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
About the study
The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Must have completed Study 111-301
- Female >= 10 years old or who have begun menses must have a negative pregnancy test at the Baseline Visit and be willing to have additional pregnancy tests during the study
- If sexually active, willing to use a highly effective method of contraception while participating in the study
- Are willing and able to perform all study procedures
- Parent(s) or guardian(s) are willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to performance of any research-related procedure. Also, subjects under the age of majority are willing and able to provide written assent (if required by local regulations or the IRB/IEC) after the nature of the study has been explained and prior to performance of any research-related procedure. Subjects who reach the age of majority in their country while the study is ongoing will be asked to provide their own written consent again upon reaching the legal age of majority.
EXCLUSION CRITERIA
Exclusion Criteria:
- Permanently discontinued BMN 111 or placebo prior to completion of the 111-301 study
- Have a clinically significant finding or arrhythmia on Baseline ECG that indicates abnormal cardiac function
- Evidence of decreased growth velocity (<1.5 cm/year) as assessed over a period of at least 6 months or of growth plate closure (proximal tibia, distal femur) through bilateral lower extremity X-rays.
- Require any investigational agent prior to completion of study period
- Current therapy with medications known to alter renal function
- Pregnant or breastfeeding or plan to become pregnant during study
- Concurrent disease or condition that, in the view of the investigator, would interfere with study participation or safety evaluations, for any reason.
- Have a condition or circumstance that, in the view of the investigator, places the subject at high risk for poor treatment compliance or for not completing the study.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Achondroplasia
Age (in years)
6+
Phase
Phase 3
Participants needed
119
Est. Completion Date
Jun 30, 2031
Treatment type
Interventional
Sponsor
BioMarin Pharmaceutical
ClinicalTrials.gov identifier
NCT03424018
Study number
111.302
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?